Cargando…
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease
Autores principales: | Cronin, Robert M., Lin, Chyongchiou J., Chiang, ChienWei, MacEwan, Sarah R., DeBaun, Michael R., Hyer, J. Madison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362533/ https://www.ncbi.nlm.nih.gov/pubmed/36883847 http://dx.doi.org/10.1182/bloodadvances.2022008965 |
Ejemplares similares
-
Vaso-Occlusive Pain and Menstruation in Sickle Cell Disease: A Focus Group Analysis
por: Day, Melissa, et al.
Publicado: (2020) -
Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events
por: Jang, Tim, et al.
Publicado: (2021) -
Targeting Neutrophil Adhesive Events to Address Vaso-Occlusive Crisis in Sickle Cell Patients
por: Morikis, Vasilios A., et al.
Publicado: (2021) -
Sickle cell vaso-occlusive crisis: it’s a gut feeling
por: Lim, Seah H., et al.
Publicado: (2016) -
Vaso-Occlusion in Sickle Cell Disease: Is Autonomic Dysregulation of the Microvasculature the Trigger?
por: Veluswamy, Saranya, et al.
Publicado: (2019)